Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2112171
Abstract: ABSTRACT Background FVIII replacement is standard treatment for hemophilia A without inhibitors, but non-factor therapies, such as emicizumab, are changing the treatment landscape. We explore the ramifications of switching treatment. Methods Pharmacy database data (July… read more here.
Keywords: alfa pegol; rurioctocog alfa; pegol emicizumab;
Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2162498
Abstract: ABSTRACT Background Owing to a lack of clinical study data, computational modeling was used to estimate activity-related bleed risk during prophylaxis with either rurioctocog alfa pegol or emicizumab. Research design and methods A pharmacokinetic (PK)-based… read more here.
Keywords: alfa pegol; rurioctocog alfa; bleed; activity ... See more keywords
Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14052
Abstract: Previous studies reported the efficacy and safety profile of extended half‐life PEGylated recombinant factor VIII (FVIII) rurioctocog alfa pegol (TAK‐660, SHP660, BAX 855) in preventing bleeding in haemophilia A patients. read more here.
Keywords: long term; safety; alfa pegol; haemophilia long ... See more keywords
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207231166779
Abstract: Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date… read more here.
Keywords: damoctocog alfa; safety; alfa pegol; study ... See more keywords
Excellent Clinical and Pharmacokinetic Real-World Experience after Switching to Rurioctocog ALFA Pegol
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142027
Abstract: Background:Prophylactic treatment with standard half-life coagulation factors (SHL) requires 3-4 weekly periodic infusions. Extended half-life (EHL) factor VIII (FVIII) provides improvements in half-life (t1/2) and area under the curve (AUC) of 1.3 and 1.25 times… read more here.
Keywords: rfviii ehl; rfviii; alfa pegol; half life ... See more keywords